onxeo
  • English
  • Français
>>>>
    • News
    • Agenda
    • Subscribe to news

Get to know AsiDNA

View corporate presentation

BECOME A PARTNER
BECOME A SHAREHOLDER

NEWS >

Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNA™, a First-In-Class DNA Damage Response Inhibitor

Boursocap / Les Echos – Investir Event

AGENDA >

Conference call on the Interim Results from Phase 1 Study of AsiDNA™

November 5, 2018 - 5:30 pm CET / 11:30 am ET

back up ↑
  • Terms of use
  • Contact
© Copyright 2018 onxeo | The sections “The group”, “Our products”, “Partnerships”, “Investors”, “Media” are dedicated to investors. | Webdesign : Limbus Studio